A phase I, single-centre, open-label, fixed-dose study of the safety and efficacy of up- to three-days application of 0.05% PEP005 [ingenol mebutate] topical gel in the treatment of patients with common wart(s) (Verruca[e] vulgaris) on the dorsal hand

Trial Profile

A phase I, single-centre, open-label, fixed-dose study of the safety and efficacy of up- to three-days application of 0.05% PEP005 [ingenol mebutate] topical gel in the treatment of patients with common wart(s) (Verruca[e] vulgaris) on the dorsal hand

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Ingenol mebutate (Primary)
  • Indications Warts
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Feb 2008 Status changed from recruiting to withdrawn prior to recruitment.
    • 04 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top